Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics

被引：25

作者：

Gyawali, Bishal ^{[1
,2
,3
]}

West, Howard ^{[4
]}

机构：

[1] Queens Univ, Dept Oncol, Kingston, ON, Canada

[2] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada

[3] Queens Univ, Div Canc Care & Epidemiol, Kingston, ON, Canada

[4] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

CELL LUNG-CANCER; CHEMOTHERAPY; SURVIVAL;

D O I：

10.1200/JCO.20.01762

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：175 / +

页数：4

共 12 条

[1] Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J].

DeMatteo, Ronald P. ;

Ballman, Karla V. ;

Antonescu, Cristina R. ;

Maki, Robert G. ;

Pisters, Peter W. T. ;

Demetri, George D. ;

Blackstein, Martin E. ;

Blanke, Charles D. ;

von Mehren, Margaret ;

Brennan, Murray F. ;

Patel, Shreyaskumar ;

McCarter, Martin D. ;

Polikoff, Jonathan A. ;

Tan, Benjamin R. ;

Owzar, Kouros .

LANCET, 2009, 373 (9669) :1097-1104

[2] ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer [J].

Govindan, Ramaswamy ;

Mandrekar, Sumithra J. ;

Gerber, David E. ;

Oxnard, Geoffrey R. ;

Dahlberg, Suzanne E. ;

Chaft, Jamie ;

Malik, Shakun ;

Mooney, Margaret ;

Abrams, Jeffrey S. ;

Jaenne, Pasi A. ;

Gandara, David R. ;

Ramalingam, Suresh S. ;

Vokes, Everett E. .

CLINICAL CANCER RESEARCH, 2015, 21 (24) :5439-5444

[3] Problems of stopping trials early [J].

Guyatt, Gordon H. ;

Briel, Matthias ;

Glasziou, Paul ;

Bassler, Dirk ;

Montori, Victor M. .

BMJ-BRITISH MEDICAL JOURNAL, 2012, 344

[4] Making adjuvant therapy decisions with uncertain data [J].

Gyawali, B. ;

Prasad, V. .

ANNALS OF ONCOLOGY, 2019, 30 (03) :361-364

[5] Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non-Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer? [J].

Langer, Corey J. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3303-3306

[6] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer [J].

Leonetti, Alessandro ;

Sharma, Sugandhi ;

Minari, Roberta ;

Perego, Paola ;

Giovannetti, Elisa ;

Tiseo, Marcello .

BRITISH JOURNAL OF CANCER, 2019, 121 (09) :725-737

[7]

Maemondo M, 2020, J CLIN ONCOL, V38

[8] Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data [J].

Mauguen, Audrey ;

Pignon, Jean-Pierre ;

Burdett, Sarah ;

Domerg, Caroline ;

Fisher, David ;

Paulus, Rebecca ;

Mandrekar, Samithra J. ;

Belani, Chandra P. ;

Shepherd, Frances A. ;

Eisen, Tim ;

Pang, Herbert ;

Collette, Laurence ;

Sause, William T. ;

Dahlberg, Suzanne E. ;

Crawford, Jeffrey ;

O'Brien, Mary ;

Schild, Steven E. ;

Parmar, Mahesh ;

Tierney, Jayne F. ;

Le Pechoux, Cecile ;

Michiels, Stefan .

LANCET ONCOLOGY, 2013, 14 (07) :619-626

[9] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer [J].

Wu, Yi-Long ;

Tsuboi, Masahiro ;

He, Jie ;

John, Thomas ;

Grohe, Christian ;

Majem, Margarita ;

Goldman, Jonathan W. ;

Laktionov, Konstantin ;

Kim, Sang-We ;

Kato, Terufumi ;

Vu, Huu-Vinh ;

Lu, Shun ;

Lee, Kye-Young ;

Akewanlop, Charuwan ;

Yu, Chong-Jen ;

de Marinis, Filippo ;

Bonanno, Laura ;

Domine, Manuel ;

Shepherd, Frances A. ;

Zeng, Lingmin ;

Hodge, Rachel ;

Atasoy, Ajlan ;

Rukazenkov, Yuri ;

Herbst, Roy S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18) :1711-1723

[10]

Wu YL, 2020, J CLIN ONCOL, V38

← 1 2 →